Fisher Clark, Janda Allison M, Zhao Xiwen, Deng Yanhong, Bardia Amit, Yanez N David, Burns Michael L, Aziz Michael F, Treggiari Miriam, Mathis Michael R, Lin Hung-Mo, Schonberger Robert B
From the Department of Anesthesiology, Yale School of Medicine, New Haven, Connecticut.
Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan.
Anesth Analg. 2025 May 1;140(5):1016-1027. doi: 10.1213/ANE.0000000000007128.
Although high-opioid anesthesia was long the standard for cardiac surgery, some anesthesiologists now favor multimodal analgesia and low-opioid anesthetic techniques. The typical cardiac surgery opioid dose is unclear, and the degree to which patients, anesthesiologists, and institutions influence this opioid dose is unknown.
We reviewed data from nonemergency adult cardiac surgeries requiring cardiopulmonary bypass performed at 30 academic and community hospitals within the Multicenter Perioperative Outcomes Group registry from 2014 through 2021. Intraoperative opioid administration was measured in fentanyl equivalents. We used hierarchical linear modeling to attribute opioid dose variation to the institution where each surgery took place, the primary attending anesthesiologist, and the specifics of the surgical patient and case.
Across 30 hospitals, 794 anesthesiologists, and 59,463 cardiac cases, patients received a mean of 1139 (95% confidence interval [CI], 1132-1146) fentanyl mcg equivalents of opioid, and doses varied widely (standard deviation [SD], 872 µg). The most frequently used opioids were fentanyl (86% of cases), sufentanil (16% of cases), hydromorphone (12% of cases), and morphine (3% of cases). 0.6% of cases were opioid-free. 60% of dose variation was explainable by institution and anesthesiologist. The median difference in opioid dose between 2 randomly selected anesthesiologists across all institutions was 600 µg of fentanyl (interquartile range [IQR], 283-1023 µg). An anesthesiologist's intraoperative opioid dose was strongly correlated with their frequency of using a sufentanil infusion (r = 0.81), but largely uncorrelated with their use of nonopioid analgesic techniques (|r| < 0.3).
High-dose opioids predominate in cardiac surgery, with substantial dose variation from case to case. Much of this variation is attributable to practice variability rather than patient or surgical differences. This suggests an opportunity to optimize opioid use in cardiac surgery.
尽管高剂量阿片类药物麻醉长期以来一直是心脏手术的标准,但现在一些麻醉医生倾向于多模式镇痛和低剂量阿片类药物麻醉技术。典型的心脏手术阿片类药物剂量尚不清楚,患者、麻醉医生和医疗机构对该阿片类药物剂量的影响程度也未知。
我们回顾了2014年至2021年在多中心围手术期结局研究组登记处的30家学术和社区医院进行的需要体外循环的非急诊成人心脏手术的数据。术中阿片类药物的使用量以芬太尼当量来衡量。我们使用分层线性模型将阿片类药物剂量变化归因于每例手术所在的机构、主刀麻醉医生以及手术患者和病例的具体情况。
在30家医院、794名麻醉医生和59463例心脏手术病例中,患者平均接受了1139(95%置信区间[CI],1132 - 1146)微克芬太尼当量的阿片类药物,且剂量差异很大(标准差[SD],872微克)。最常用的阿片类药物是芬太尼(86%的病例)、舒芬太尼(16%的病例)、氢吗啡酮(12%的病例)和吗啡(3%的病例)。0.6%的病例未使用阿片类药物。60%的剂量差异可由机构和麻醉医生来解释。在所有机构中,随机选择的两名麻醉医生之间阿片类药物剂量的中位数差异为600微克芬太尼(四分位间距[IQR],283 - 1023微克)。麻醉医生术中阿片类药物剂量与其使用舒芬太尼输注的频率密切相关(r = 0.81),但与其使用非阿片类镇痛技术的相关性不大(|r| < 0.3)。
心脏手术中高剂量阿片类药物占主导,病例之间的剂量差异很大。这种差异很大程度上归因于实践的变异性,而非患者或手术的差异。这表明在心脏手术中优化阿片类药物使用存在机会。